Tivic Health Rebrands as Valion Bio, Advances Entolimod for Acute Radiation Syndrome with FDA Fast Track Status

Key Takeaways

• Tivic Health Systems has rebranded as Valion Bio to reflect its transformation into a late-stage biopharmaceutical company
• Lead drug Entolimod has received FDA Fast Track and Orphan Drug designations for treating Acute Radiation Syndrome
• The company is advancing Entolimod under FDA’s Animal Rule pathway, which reduces clinical execution risk by enabling approval based on animal efficacy data

---

Tivic Health Systems has officially rebranded as Valion Bio, marking the company’s completed transformation into a late-stage biopharmaceutical company focused on developing government-backed medical countermeasures with multiple revenue stream potential.

Entolimod: A Novel Approach to Radiation Protection

Valion Bio’s flagship asset, Entolimod™, represents a breakthrough in radiation medicine as a novel Toll-like receptor 5 (TLR5) agonist. The drug candidate features a differentiated, dual-utility profile that positions it uniquely in the medical countermeasure space.

As a medical countermeasure for Acute Radiation Syndrome (ARS), Entolimod addresses a critical unmet medical need in both civilian and military applications. The condition, which can result from nuclear accidents or radiological attacks, currently has limited treatment options.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Regulatory Advantages Reduce Development Risk

The FDA has granted Entolimod both Fast Track and Orphan Drug designations, providing significant regulatory advantages including more frequent FDA meetings, rolling review of application components, and potential priority review.

Crucially, Valion Bio is advancing Entolimod under the FDA’s Animal Rule pathway. This specialized regulatory framework enables drug approval based on animal efficacy data when human trials are not feasible or ethical due to the nature of the condition being treated.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Strategic Positioning for Multiple Revenue Streams

The rebrand to Valion Bio reflects the company’s evolution from its previous focus areas to concentrate on this high-potential biopharmaceutical asset. The government-backed nature of Entolimod development, combined with its dual-utility profile, positions the company for potential multiple revenue streams from both government procurement and commercial applications.

This strategic transformation comes at a time when medical countermeasures are receiving increased attention from government agencies and investors, driven by growing awareness of radiological threats and emergency preparedness needs.

---

Frequently Asked Questions

What does this rebrand mean for patients with Acute Radiation Syndrome?

The rebrand signals Valion Bio’s focused commitment to advancing Entolimod through development, potentially bringing the first novel ARS treatment to market faster through dedicated resources and expertise.

When will Entolimod be available for patients?

While specific timelines weren’t disclosed, the FDA’s Animal Rule pathway and Fast Track designation are designed to expedite development, though the company must still complete required animal studies and regulatory submissions.

How does Entolimod compare to existing ARS treatments?

Entolimod’s novel TLR5 agonist mechanism and dual-utility profile differentiate it from current limited ARS treatment options, potentially offering improved efficacy and broader applications as a medical countermeasure.

Related coverage

• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
• Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
• FDA approves Dupixent for COPD with eosinophilic phenotype